Literature DB >> 19423715

Pseudomonas aeruginosa microevolution during cystic fibrosis lung infection establishes clones with adapted virulence.

Alessandra Bragonzi1, Moira Paroni, Alessandro Nonis, Nina Cramer, Sara Montanari, Joanna Rejman, Clelia Di Serio, Gerd Döring, Burkhard Tümmler.   

Abstract

RATIONALE: During long-term lung infection in patients with cystic fibrosis (CF), Pseudomonas aeruginosa strains develop mutations leading to clonal expansion. This microevolution is believed to be correlated with a reduced virulence.
OBJECTIVES: We tested this hypothesis in models of lung infection, using mice with different genetic backgrounds.
METHODS: From infected airways of six patients with CF, 25 P. aeruginosa clones were isolated during a period of up to 16.3 years and genotypically and phenotypically characterized. Virulence of the 8 early, 6 intermediate, and 11 late CF isolates and 5 environmental strains was assessed by monitoring acute mortality versus survival and P. aeruginosa chronic persistence versus lung clearance in mice of different genetic backgrounds, including CF mice.
MEASUREMENTS AND MAIN RESULTS: Different patients harbored clonally unrelated strains, but early, intermediate, and late P. aeruginosa isolates from single patients were clonally related, allowing comparative in vivo analysis. Although late isolates were attenuated in causing acute mortality in the mouse models, compared with early and intermediate clonal isolates and environmental strains, they did not differ from early and intermediate clonal isolates in their capacity to establish chronic infection and cause extensive inflammation in the murine respiratory tract.
CONCLUSIONS: Our findings indicate that clonal expansion of P. aeruginosa strains during microevolution within CF lungs leads to populations with altered but not reduced virulence. These P. aeruginosa clones with adapted virulence play a critical role in the pathogenesis of chronic infections and may serve to define virulence determinants as targets for novel therapies.

Entities:  

Mesh:

Year:  2009        PMID: 19423715     DOI: 10.1164/rccm.200812-1943OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  114 in total

1.  Long term chronic Pseudomonas aeruginosa airway infection in mice.

Authors:  Marcella Facchini; Ida De Fino; Camilla Riva; Alessandra Bragonzi
Journal:  J Vis Exp       Date:  2014-03-17       Impact factor: 1.355

2.  Pyochelin potentiates the inhibitory activity of gallium on Pseudomonas aeruginosa.

Authors:  Emanuela Frangipani; Carlo Bonchi; Fabrizia Minandri; Francesco Imperi; Paolo Visca
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

3.  Role of Iron Uptake Systems in Pseudomonas aeruginosa Virulence and Airway Infection.

Authors:  Fabrizia Minandri; Francesco Imperi; Emanuela Frangipani; Carlo Bonchi; Daniela Visaggio; Marcella Facchini; Paolo Pasquali; Alessandra Bragonzi; Paolo Visca
Journal:  Infect Immun       Date:  2016-07-21       Impact factor: 3.441

Review 4.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 5.  Molecular Mechanisms of Biofilm Infection: Biofilm Virulence Factors.

Authors:  Priscilla L Phillips; Gregory S Schultz
Journal:  Adv Wound Care (New Rochelle)       Date:  2012-06       Impact factor: 4.730

6.  Developing an international Pseudomonas aeruginosa reference panel.

Authors:  Anthony De Soyza; Amanda J Hall; Eshwar Mahenthiralingam; Pavel Drevinek; Wieslaw Kaca; Zuzanna Drulis-Kawa; Stoyanka R Stoitsova; Veronika Toth; Tom Coenye; James E A Zlosnik; Jane L Burns; Isabel Sá-Correia; Daniel De Vos; Jean-Paul Pirnay; Timothy J Kidd; David Reid; Jim Manos; Jens Klockgether; Lutz Wiehlmann; Burkhard Tümmler; Siobhán McClean; Craig Winstanley
Journal:  Microbiologyopen       Date:  2013-11-11       Impact factor: 3.139

7.  Myriocin treatment of CF lung infection and inflammation: complex analyses for enigmatic lipids.

Authors:  Anna Caretti; Michele Vasso; Fabiola Tecla Bonezzi; Andrea Gallina; Marco Trinchera; Alice Rossi; Raffaella Adami; Josefina Casas; Monica Falleni; Delfina Tosi; Alessandra Bragonzi; Riccardo Ghidoni; Cecilia Gelfi; Paola Signorelli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-04-24       Impact factor: 3.000

8.  Pseudomonas aeruginosa Condensins Support Opposite Differentiation States.

Authors:  Hang Zhao; April L Clevenger; Jerry W Ritchey; Helen I Zgurskaya; Valentin V Rybenkov
Journal:  J Bacteriol       Date:  2016-10-07       Impact factor: 3.490

Review 9.  The Collaborative Cross mouse model for dissecting genetic susceptibility to infectious diseases.

Authors:  Hanifa Abu Toamih Atamni; Aysar Nashef; Fuad A Iraqi
Journal:  Mamm Genome       Date:  2018-08-24       Impact factor: 2.957

10.  Pseudomonas aeruginosa exploits lipid A and muropeptides modification as a strategy to lower innate immunity during cystic fibrosis lung infection.

Authors:  Cristina Cigana; Laura Curcurù; Maria Rosaria Leone; Teresa Ieranò; Nicola Ivan Lorè; Irene Bianconi; Alba Silipo; Flora Cozzolino; Rosa Lanzetta; Antonio Molinaro; Maria Lina Bernardini; Alessandra Bragonzi
Journal:  PLoS One       Date:  2009-12-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.